A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 01 Nov 2017 Planned End Date changed from 19 Dec 2017 to 18 Oct 2018.
- 01 Nov 2017 Planned primary completion date changed from 19 Dec 2017 to 18 Oct 2018.
- 23 Oct 2017 Planned End Date changed from 1 May 2024 to 19 Dec 2017.